The overexpression of the sigma-2 receptor in various types of cancers, including breast carcinoma, melanoma, prostate cancer, pancreatic tumors, and brain tumors [14, 27], has caused sigma-2 receptor ligands to be potential drugs for monitoring and treating cancer [18, 28]. Here, TMEM97 is linked to pancreatic neoplasm.